Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Healsea® Children is a seawater-based nasal spray supplemented with a natural Symbiofilm® extract (0.02%) isolated from marine bacteria. Symbiofilm has antibiofilm activity against various bacterial pathogens involved in respiratory tract infections.Healsea® Children is indicated in the cleaning and moistening of nasal mucosa during common cold and rhinitis for children above 6 years.
This non interventional post-market clinical investigation aimed to confirm the benefit of Healsea® Children in real life setting in children with perennial allergy who are more prone to common cold.
Healsea® Children is a seawater-based nasal spray supplemented with a natural Symbiofilm® extract (0.02%) isolated from marine bacteria. Symbiofilm® is an exopolymeric composition with emulsifying properties, in vitro antibiofilm activity and detachment properties against various bacterial pathogens involved in respiratory tract infections. Symbiofilm® has no bacteriostatic nor bactericidal activities. Healsea® Children is indicated in the cleaning and moistening of nasal mucosa during common cold and rhinitis.
The common cold is an acute viral infection of the upper respiratory tract, involving, to variable degrees, sneezing, nasal congestion and discharge (rhinorrhea), sore throat, cough, low-grade fever, headache, and malaise (1). It can be caused by members of several families of viruses; the most common are rhinoviruses. Acute viral rhinitis is generally self-limiting. In children where the illness is not self-limiting and extends beyond 7-10 days, many agree that a bacterial infection is likely (1). Bacterial over infections and progression to a chronic state are favoured by the formation of biofilms, which facilitate bacterial growth and persistence as well as reducing antibiotic efficacy (2-3).
Allergic diseases may play a particular role in promoting the respiratory infection recurrences (4). The physiological immune response is impaired in allergic subjects and allergic inflammation favours predisposition to respiratory infections. Subjects with allergic disorders may have functional defect of type 1 immune response that is relevant in fighting infections (5-6).
Allergic rhinitis (AR) may affect up to 40% of the paediatric population. Nasal symptoms are caused by exposure to an allergen to which a patient is sensitized.
AR is characterized by typical nasal symptoms and immunoglobulin E (IgE) -mediated inflammation. The allergic inflammatory process releases many cytokines and other proinflammatory proteins. Inflammation caused by nasal allergy leads to obstruction, fluid accumulation and acute disease. If these diseases are unsuccessfully treated, a chronic state of inflammation, obstruction, and infection develops that can cause mucosal damage and, ultimately, chronic disease (7).
For these reasons, the paediatric IgE-dependent allergic population that is more prone to common cold represents a suitable target for Healsea® Children (8-9).
During this prospective post-market clinical investigation, IgE-dependent allergic children with early symptoms of infectious rhinitis will be followed, children being treated with Healsea® Children on top of common cold conventional therapies or with conventional therapies only (excluded nasal irrigation).
Conventional therapies for non-complicated infectious rhinitis are symptomatic but are not without side effects. For example, decongestant use can increase blood pressure, antihistamine intake is associated with drowsiness.
Healsea® Children represents an interesting alternative that can not only improve acute infectious rhinitis symptomatology but could also limit the complication and progression to chronic state.
This non interventional post-market clinical investigation aimed to confirm the benefit of Healsea® Children in a real life setting in children with perennial allergy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healsea® Children: isotonic seawater based nasal spray supplemented with natural Symbiofilm® extract | Children will receive Healsea® Children nasal spray on top of conventional therapies for common cold, as needed. |
| |
| Conventional therapies | Children will receive conventional therapies for common cold as needed, nasal irrigation excluded |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Healsea® Children | Device | Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed |
| Measure | Description | Time Frame |
|---|---|---|
| AUC (Area Under Curve) of the Wisconsin Upper Respiratory Symptoms Survey for Kids (WURSS-K) During the 10-day Treatment Period | The WURSS-K will be assessed once daily, from Day1 to Day10 (treatment period) WURSS-K is a 3-dimensional structure questionnaire specifically designed for children 4 to 10 years of age. It includes 6 items assessing symptoms (symptoms score: runny nose, stuffy nose, sneezing, sore throat, cough, feeling tired), 7 items assessing functional impairments (quality of life score: think, sleep, breathe, talk, walk/climb stairs/exercise, go to school, play with friends), 1 item assessing global severity. All these items are scored from 0 (absent or no impairment) through 1 (a little bad), 2 (bad) and 3 (very bad). The AUC value of the WURSS-K during the 10 day- treatment period is comprised between 0 WURSS-K score*day (no impairement) and 420 WURSS-K score *day (maximal impairement) | Cumulative AUC of the WURSS score assessed from Day 1 to Day 10 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Days With Runny Nose | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of each common cold symptoms in both groups. Runny nose is the item 2 | Number of days with runny nose during the 10-day treatment period and a follow-up of 20 days, up to 30 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The study population comprises children 6 to10 years old with perennial allergy and early symptoms of common cold.
The recruitment will be competitive in both group, exposed to Healsea® Children or not exposed to Healsea® Children. However, when 100 patients will be recruited in one group, the recruitment will be stopped in this group but will continue in the other group until 100 patients to be enrolled.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrzej EMERYK, MD, PhD | University Children Hospital, Lublin, Poland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Bialystok | 15-010 | Poland | |||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32077450 | Background | Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Meco C, Matricardi PM, O'Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia P, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kawauchi H, Kjeldsen A, Klimek L, Krzeski A, Kopacheva Barsova G, Kim SW, Lal D, Letort JJ, Lopatin A, Mahdjoubi A, Mesbahi A, Netkovski J, Nyenbue Tshipukane D, Obando-Valverde A, Okano M, Onerci M, Ong YK, Orlandi R, Otori N, Ouennoughy K, Ozkan M, Peric A, Plzak J, Prokopakis E, Prepageran N, Psaltis A, Pugin B, Raftopulos M, Rombaux P, Riechelmann H, Sahtout S, Sarafoleanu CC, Searyoh K, Rhee CS, Shi J, Shkoukani M, Shukuryan AK, Sicak M, Smyth D, Sindvongs K, Soklic Kosak T, Stjarne P, Sutikno B, Steinsvag S, Tantilipikorn P, Thanaviratananich S, Tran T, Urbancic J, Valiulius A, Vasquez de Aparicio C, Vicheva D, Virkkula PM, Vicente G, Voegels R, Wagenmann MM, Wardani RS, Welge-Lussen A, Witterick I, Wright E, Zabolotniy D, Zsolt B, Zwetsloot CP. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants were outpatients visiting a physician in Polish hospitals or private practices at the onset of a common cold. The first patient was screened and enrolled on 14th of February 2022 and the last patient on 20th October 2022.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Healsea® Children: Isotonic Seawater Based Nasal Spray Supplemented With Natural Symbiofilm® Extract | Children will receive Healsea® Children nasal spray on top of conventional therapies for common cold, as needed. Healsea® Children: Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed Conventional therapies for common cold: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics) |
| FG001 | Conventional Therapies | Children will receive conventional therapies for common cold as needed, nasal irrigation excluded Conventional therapies for common cold: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics) |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Healsea® Children: Isotonic Seawater Based Nasal Spray Supplemented With Natural Symbiofilm® Extract | Children will receive Healsea® Children nasal spray on top of conventional therapies for common cold, as needed. Healsea® Children: Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed Conventional therapies for common cold: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | AUC (Area Under Curve) of the Wisconsin Upper Respiratory Symptoms Survey for Kids (WURSS-K) During the 10-day Treatment Period | The WURSS-K will be assessed once daily, from Day1 to Day10 (treatment period) WURSS-K is a 3-dimensional structure questionnaire specifically designed for children 4 to 10 years of age. It includes 6 items assessing symptoms (symptoms score: runny nose, stuffy nose, sneezing, sore throat, cough, feeling tired), 7 items assessing functional impairments (quality of life score: think, sleep, breathe, talk, walk/climb stairs/exercise, go to school, play with friends), 1 item assessing global severity. All these items are scored from 0 (absent or no impairment) through 1 (a little bad), 2 (bad) and 3 (very bad). The AUC value of the WURSS-K during the 10 day- treatment period is comprised between 0 WURSS-K score*day (no impairement) and 420 WURSS-K score *day (maximal impairement) | All included subjects who used the investigational medical device at least once and with non-missing value at Day1 and at least another non-missing time point between Day2 and Day10. Otherwise, the AUC was missing. | Posted | Mean | Standard Deviation | scores on WURSS-K scale* days | Cumulative AUC of the WURSS score assessed from Day 1 to Day 10 |
Adverse events were collected during a 10-day treatment period and a follow-up period of 20 days, up to 30 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Healsea® Children: Isotonic Seawater Based Nasal Spray Supplemented With Natural Symbiofilm® Extract | Children will receive Healsea® Children nasal spray on top of conventional therapies for common cold, as needed. Healsea® Children: Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed Conventional therapies for common cold: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics) |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| cough | Respiratory, thoracic and mediastinal disorders | MedDRA 25.0 | Systematic Assessment |
This is a not blinded, nor placebo-controlled investigation
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr Bernard Gout | Pharmndev Experts | +41798659000 | bgout@pharmndev.ch |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Sep 8, 2021 | Dec 20, 2023 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jan 26, 2023 | Dec 20, 2023 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D003139 | Common Cold |
| D006967 | Hypersensitivity |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D010850 | Picornaviridae Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D003080 | Cold Temperature |
| ID | Term |
|---|---|
| D013696 | Temperature |
| D013816 | Thermodynamics |
| D055585 | Physical Phenomena |
| D014887 | Weather |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Conventional therapies for common cold | Other | Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics) |
|
| Number of Days With Stuffy Nose | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of each common cold symptoms in both groups. Stuffy nose is the item 3. | Number of days with stuffy nose during the 10-day treatment period and a follow-up period of 20 days, up to 30 days |
| Number of Days With Sneezing | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of common cold symptoms in both groups. Sneezing is the item 4. | Number of days with sneezing during the 10-day treatment period and a follow-up of 20 days, up to 30 days |
| Number of Days With Sore Throat | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of each common cold symptoms in both groups. Sore throat is the item 5. | Number of days with sore throat during the 10-day treatment period and a follow-up of 20 days, up to 30 days |
| Number of Days With Cough | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of each common cold symptoms in both groups. Cough is the item 6. | Number of days with cough during the 10-day treatment period and a follow-up of 20 days, up to 30 days |
| Number of Days With "Feeling Tired" | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of each common cold symptoms in both groups. Feeling tired is the item 7. | Number of days with "feeling tired" during the 10-day treatment period and a follow-up of 20 days, up to 30 days |
| Respiratory Complication Requiring Antibiotic Prescription After the10-day Treatment Period | The number of subjects who develop respiratory complication requiring antibiotic prescription during a 20-day follow-up period after the treatment period will be assessed in both groups and compared | Number of subjects with respiratory complications during the 20-day follow-up period |
| Number of Participants With Use of Concomitant Treatments | Number of subjects who took at least one concomitant treatment (antibiotics, antipyretics, systemic or local mucolytics, decongestants, antitussives, systemic and topical corticosteroids) that may impact symptoms of common cold and comparaison between groups | During 10-day treatment period and a follow-up period of 20 days, up to 30 days |
| Bialystok |
| 15-430 |
| Poland |
| Research Site | Bydgoszcz | 85-048 | Poland |
| Research Site | Dys | 21-003 | Poland |
| Research Site | Głowno | 95-015 | Poland |
| Research Site | Krakow | 30-644 | Poland |
| Research Site | Lublin | 20-093 | Poland |
| Research Site | Lublin | 20-141 | Poland |
| Research Site | Lublin | 20-552 | Poland |
| Research Site | Lublin | 20-803 | Poland |
| Research Site | Lublin | 20-865 | Poland |
| Research Site | Rzeszów | 35-061 | Poland |
| Research Site | Tarnów | 33-100 | Poland |
| Research Site | Warsaw | 04-314 | Poland |
| Research Site | Łomża | 18-402 | Poland |
| 31295420 | Background | Yan J, Bassler BL. Surviving as a Community: Antibiotic Tolerance and Persistence in Bacterial Biofilms. Cell Host Microbe. 2019 Jul 10;26(1):15-21. doi: 10.1016/j.chom.2019.06.002. |
| 25875875 | Background | Rabin N, Zheng Y, Opoku-Temeng C, Du Y, Bonsu E, Sintim HO. Biofilm formation mechanisms and targets for developing antibiofilm agents. Future Med Chem. 2015;7(4):493-512. doi: 10.4155/fmc.15.6. |
| 32039733 | Background | Varricchio A, La Mantia I, Brunese FP, Ciprandi G. Inflammation, infection, and allergy of upper airways: new insights from national and real-world studies. Ital J Pediatr. 2020 Feb 10;46(1):18. doi: 10.1186/s13052-020-0782-z. |
| 16846459 | Background | Ciprandi G, Tosca MA, Fasce L. Allergic children have more numerous and severe respiratory infections than non-allergic children. Pediatr Allergy Immunol. 2006 Aug;17(5):389-91. doi: 10.1111/j.1399-3038.2006.00413.x. |
| 17578494 | Background | Cirillo I, Marseglia G, Klersy C, Ciprandi G. Allergic patients have more numerous and prolonged respiratory infections than nonallergic subjects. Allergy. 2007 Sep;62(9):1087-90. doi: 10.1111/j.1398-9995.2007.01401.x. Epub 2007 Jun 18. |
| 27434218 | Background | Eifan AO, Durham SR. Pathogenesis of rhinitis. Clin Exp Allergy. 2016 Sep;46(9):1139-51. doi: 10.1111/cea.12780. |
| 32889648 | Background | De Corso E, Lucidi D, Cantone E, Ottaviano G, Di Cesare T, Seccia V, Paludetti G, Galli J. Clinical Evidence and Biomarkers Linking Allergy and Acute or Chronic Rhinosinusitis in Children: a Systematic Review. Curr Allergy Asthma Rep. 2020 Sep 5;20(11):68. doi: 10.1007/s11882-020-00967-9. |
| 30753196 | Background | Lin SW, Wang SK, Lu MC, Wang CL, Koo M. Acute rhinosinusitis among pediatric patients with allergic rhinitis: A nationwide, population-based cohort study. PLoS One. 2019 Feb 12;14(2):e0211547. doi: 10.1371/journal.pone.0211547. eCollection 2019. |
| BG001 | Conventional Therapies | Children will receive conventional therapies for common cold as needed, nasal irrigation excluded Conventional therapies for common cold: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics) |
| BG002 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Symptoms of acute rhinitis at baseline: temperature | Mean | Standard Deviation | Degrees Celcius |
|
| Symptoms of acute rhinitis at baseline | Symptoms of headache, muscle ache, chilliness, sore throat, blocked nose, runny nose, cough, sneezing at baseline according to a physician-rated symptom score for each symptom; scale: 0 → 3 [0: no symptom to 3: severe intensity]) | Mean | Standard Deviation | units on a scale |
|
| ID | Title | Description |
|---|---|---|
| OG000 | Healsea® Children: Isotonic Seawater Based Nasal Spray Supplemented With Natural Symbiofilm® Extract | Children will receive Healsea® Children nasal spray on top of conventional therapies for common cold, as needed. Healsea® Children: Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed Conventional therapies for common cold: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics) |
| OG001 | Conventional Therapies | Children will receive conventional therapies for common cold as needed, nasal irrigation excluded Conventional therapies for common cold: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics) |
|
|
|
| Secondary | Number of Days With Runny Nose | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of each common cold symptoms in both groups. Runny nose is the item 2 | All included subjects who used the investigational medical device at least once | Posted | Mean | Standard Error | Day | Number of days with runny nose during the 10-day treatment period and a follow-up of 20 days, up to 30 days |
|
|
|
|
| Secondary | Number of Days With Stuffy Nose | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of each common cold symptoms in both groups. Stuffy nose is the item 3. | FAS | Posted | Mean | Standard Error | Day | Number of days with stuffy nose during the 10-day treatment period and a follow-up period of 20 days, up to 30 days |
|
|
|
|
| Secondary | Number of Days With Sneezing | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of common cold symptoms in both groups. Sneezing is the item 4. | FAS | Posted | Mean | Standard Error | Day | Number of days with sneezing during the 10-day treatment period and a follow-up of 20 days, up to 30 days |
|
|
|
|
| Secondary | Number of Days With Sore Throat | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of each common cold symptoms in both groups. Sore throat is the item 5. | FAS | Posted | Mean | Standard Error | Day | Number of days with sore throat during the 10-day treatment period and a follow-up of 20 days, up to 30 days |
|
|
|
|
| Secondary | Number of Days With Cough | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of each common cold symptoms in both groups. Cough is the item 6. | FAS | Posted | Mean | Standard Error | Day | Number of days with cough during the 10-day treatment period and a follow-up of 20 days, up to 30 days |
|
|
|
|
| Secondary | Number of Days With "Feeling Tired" | During the treatment period, the WURSS-K will be assessed once daily. After D10, the WURSS-K will be assessed once daily until the subject feels not sick for two consecutive days. Items 2 to 7 will be used to assess the duration of each common cold symptoms in both groups. Feeling tired is the item 7. | FAS | Posted | Mean | Standard Error | Day | Number of days with "feeling tired" during the 10-day treatment period and a follow-up of 20 days, up to 30 days |
|
|
|
|
| Secondary | Respiratory Complication Requiring Antibiotic Prescription After the10-day Treatment Period | The number of subjects who develop respiratory complication requiring antibiotic prescription during a 20-day follow-up period after the treatment period will be assessed in both groups and compared | FAS | Posted | Count of Participants | Participants | Number of subjects with respiratory complications during the 20-day follow-up period |
|
|
|
|
| Secondary | Number of Participants With Use of Concomitant Treatments | Number of subjects who took at least one concomitant treatment (antibiotics, antipyretics, systemic or local mucolytics, decongestants, antitussives, systemic and topical corticosteroids) that may impact symptoms of common cold and comparaison between groups | Posted | Number | participants | During 10-day treatment period and a follow-up period of 20 days, up to 30 days |
|
|
|
|
| 0 |
| 101 |
| 0 |
| 101 |
| 17 |
| 101 |
| EG001 | Conventional Therapies | Children will receive conventional therapies for common cold as needed, nasal irrigation excluded Conventional therapies for common cold: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics) | 0 | 85 | 0 | 85 | 23 | 85 |
| Nasal obstruction | Respiratory, thoracic and mediastinal disorders | MedDRA 25.0 | Systematic Assessment |
|
| Rhinorrhea | Respiratory, thoracic and mediastinal disorders | MedDRA 25.0 | Systematic Assessment |
|
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA 25.0 | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA 25.0 | Systematic Assessment |
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 25.0 | Systematic Assessment |
|
| Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | MedDRA 25.0 | Systematic Assessment |
|
| Pharyngitis | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
|
| Bronchitis | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
|
| Rhinitis | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
|
| conjunctivitis | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
|
| Respiratory tract infection | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
|
| Tonsilitis | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA 25.0 | Systematic Assessment |
|
| Ear pain | Ear and labyrinth disorders | MedDRA 25.0 | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA 25.0 | Systematic Assessment |
|
Not provided
| D014777 |
| Virus Diseases |
| D012140 | Respiratory Tract Diseases |
| D007154 | Immune System Diseases |
| D001272 |
| Atmosphere |
| D004777 | Environment |
| D055669 | Ecological and Environmental Phenomena |
| D001686 | Biological Phenomena |
| D008685 | Meteorological Concepts |
| D004778 | Environment and Public Health |